Trial · NCT02805660
Results by group134
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 134
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) During the First 28-day Cycle of Combination Treatment In Phase 1 | Phase 1: Dose Escalation - 50 mg | 0 | Participants | ||
| Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) During the First 28-day Cycle of Combination Treatment In Phase 1 | Phase 1: Dose Escalation - 70 mg | 0 | Participants | ||
| Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) During the First 28-day Cycle of Combination Treatment In Phase 1 | Phase 1: Dose Escalation - 90 mg | 0 | Participants | ||
| Objective Response Rate (ORR) | Phase 1: Dose Escalation - 50 mg | 0 | 95% Confidence Interval 0.0 to 52.2 | Percentage of participants | |
| Objective Response Rate (ORR) | Phase 1: Dose Escalation - 70 mg | 0 | 95% Confidence Interval 0.0 to 60.2 | Percentage of participants | |
| Objective Response Rate (ORR) | Phase 1: Dose Escalation - 90 mg | 0 | 95% Confidence Interval 0.0 to 33.6 | Percentage of participants | |
| Objective Response Rate (ORR) | Phase 2: Combination Regimen - Cohort 1 | 6.7 | 95% Confidence Interval 0.2 to 31.9 | Percentage of participants | |
| Objective Response Rate (ORR) | Phase 2: Combination Regimen - Cohort 2 | 0 | 95% Confidence Interval 0.0 to 70.8 | Percentage of participants | |
| Objective Response Rate (ORR) | Phase 2: Combination Regimen - Cohort 3 | 9.5 | 95% Confidence Interval 1.2 to 30.4 | Percentage of participants | |
| Objective Response Rate (ORR) | Phase 2: Combination Regimen - Cohort 4 | 23.1 | 95% Confidence Interval 5.0 to 53.8 | Percentage of participants | |
| Number of Participants Experiencing Treatment-Emergent Adverse Events | Phase 1: Dose Escalation - 50 mg | 5 | Participants | ||
| Number of Participants Experiencing Treatment-Emergent Adverse Events | Phase 1: Dose Escalation - 70 mg | 4 | Participants | ||
| Number of Participants Experiencing Treatment-Emergent Adverse Events | Phase 1: Dose Escalation - 90 mg | 10 | Participants | ||
| Number of Participants Experiencing Treatment-Emergent Adverse Events | Phase 2: Combination Regimen - Cohort 1 | 18 | Participants | ||
| Number of Participants Experiencing Treatment-Emergent Adverse Events | Phase 2: Combination Regimen - Cohort 2 | 3 | Participants | ||
| Number of Participants Experiencing Treatment-Emergent Adverse Events | Phase 2: Combination Regimen - Cohort 3 | 23 | Participants | ||
| Number of Participants Experiencing Treatment-Emergent Adverse Events | Phase 2: Combination Regimen - Cohort 4 | 18 | Participants | ||
| Duration of Response (DR) | Phase 2: Combination Regimen - Cohort 1 | 115 | 95% Confidence Interval NA to NA | Days | |
| Duration of Response (DR) | Phase 2: Combination Regimen - Cohort 3 | 329 | 95% Confidence Interval NA to NA | Days | |
| Duration of Response (DR) | Phase 2: Combination Regimen - Cohort 4 | NA | 95% Confidence Interval 230 to NA | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02805660/results